SHEDDING LIGHT ON PATIENT-REPORTED OUTCOME MEASURE UTILIZATION ACROSS NSCLC THERAPIES

Imfinzi (durvalumab) - AstraZeneca

Alecensa (alectinib) - Roche

Datroway (datopotamab deruxtecan-dlnk) - Daiichi Sankyo, AstraZeneca

Rozlytrek (entrectinib) - Roche

Tecentriq (atezolizumab) - Roche

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

Hernexeos (zongertinib) - Boehringer Ingelheim

Trupti Dhumal, MS, PhD 1; Sahil Bhave, MS 1; Emma A. van Eijndhoven, MSc, MA 2; Ambarish J. Ambegaonkar, PhD 1

Mar 6, 2026